Thoracic Surgery during Coronavirus Disease 2019 (COVID-19): The Experience of a Level 1 Trauma Center

Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus primarily affecting the respiratory system, was initially diagnosed in Wuhan, China, in late 2019. Identified as coronavirus disease 2019 (COVID-19) by the World Health Organization, the virus rapidly became a global pandemic. The effects on health care worldwide were unprecedented as countries adapted services to treat masses of critically ill patients.

The aim of this study is to analyze the effect that the COVID-19 pandemic had on thoracic surgery at a major trauma center during peak prevalence.

Methods Prospective unit data were collected for all patients who underwent thoracic surgery during March 2020 until May 2020 inclusive. Retrospective data were collected from an earlier comparable time period as a comparison.

Results In the aforementioned time frame, 117 thoracic surgical operations were performed under the care of four thoracic surgeons. Six operations were performed on three patients who were being treated for SARS-CoV-2. One operation was performed on a patient who had recovered from SARS-CoV-2. There were no deaths due to SARS-CoV-2 in any patient undergoing thoracic surgery.

Conclusion This study demonstrates that during the first surge of SARS-CoV-2, it was possible to adapt a thoracic oncology and trauma service without increase in mortality due to COVID-19. This was only possible due to a significant reduction in trauma referrals, cessation of benign and elective work, and the more stringent reprioritization of cancer surgery. This information is vital to learn from our experience and prepare for the predicted second surge and any similar future pandemics we might face.

Keywords

COVID-19 - coronavirus - pandemic - thoracic surgery - lung cancer

Publikationsverlauf

Eingereicht: 20. Juli 2020

Angenommen: 27. August 2020

Artikel online veröffentlicht:
20. November 2020

• References

• 1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
• 2 World Health Organization, WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed July 2, 2020.
• 3 World Health Organization, Novel Coronavirus (2019-nCoV): Situation Report – 22. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. Accessed July 2, 2020
• 4 John Hopkins University of Medicine Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed July 2, 2020
• 5 Government of UK, Coronavirus (COVID-19) cases in the UK. https://coronavirus.data.gov.uk/. Accessed July 2, 2020
• 6 Guan WJ, Ni ZY, Hu Y. China Medical Treatment Expert Group for Covid-19. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
• 7 Grasselli G, Zangrillo A, Zanella A. COVID-19 Lombardy ICU Network. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323: 1574-1581
• 8 Intensive Care National Audit & Research Centre, ICNARC report on COVID-19 in critical care: 26 June 2020. https://www.icnarc.org/DataServices/Attachments/Download/0a0738a6-dcb7-ea11-9127-00505601089b. Accessed June 30, 2020
• 9 Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020; 221 (11) 1757-1761
• 10 Li Q, Guan X, Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382 (13) 1199-1207
• 11 Pung R, Chiew CJ, Young BE. Singapore 2019 Novel Coronavirus Outbreak Research Team. et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet 2020; 395 (10229): 1039-1046
• 12 Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55 (05) 105954
• 13 World Health Organization, Global surveillance for COVID-19 caused by human infection with COVID-19 virus. https://www.who.int/docs/default-source/coronaviruse/2020-03-20-surveillance.pdf?sfvrsn=e6be6ef1_2 . Accessed July 2, 2020
• 14 World Health Organization, Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. https://apps.who.int/iris/rest/bitstreams/1272454/retrieve . Accessed July 2, 2020
• 15 COVIDSurg Collaborative. Global guidance for surgical care during the COVID-19 pandemic. Br J Surg 2020; (e-pub ahead of print) DOI: 10.1002/bjs.11646.
• 16 Cai Y, Hao Z, Gao Y. et al. Coronavirus disease 2019 in the perioperative period of lung resection: a brief report from a Single Thoracic Surgery Department in Wuhan, People's Republic of China. J Thorac Oncol 2020; 15 (06) 1065-1072
• 17 Garassino MC, Whisenant JG, Huang LC. TERAVOLT investigators. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020; 21 (07) 914-922
• 18 Yu J, Wen Ouyang, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020; 6 (07) 1108-1110
• 19 Harkin DW. Ethics for surgeons during the COVID-19 pandemic, review article. Ann Med Surg (Lond) 2020; 55: 316-319
• 20 Government of UK, UK Government Guidelines on Coronavirus. https://www.gov.uk/government/publications/ . Accessed July 2, 2020
• 21 Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020; 368 (6493): 860-868
• 22 COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an International Cohort Study. Lancet 2020; 396 (10243): 27-38
• 23 Dingemans AC, Soo RA, Jazieh AR. et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020; 15 (07) 1119-1136
• 24 National Health Services. Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf . Accessed July 2, 2020
• 25 Cancer Research UK, How coronavirus is impacting cancer services in the UK. https://scienceblog.cancerresearchuk.org/2020/04/21/how-coronavirus-is-impacting-cancer-services-in-the-uk/ . Accessed July 2, 2020
• 26 Stinner DJ, Lebrun C, Hsu JR, Jahangir AA, Mir HR. The orthopaedic trauma service and COVID-19: Practice considerations to optimize outcomes and limit exposure. J Orthop Trauma 2020; 34 (07) 333-340
• 27 Smelt J, Lovejoy C, Thakker R, Hunt I, Martin F, Tan C. Elective lung resections in the elderly: where do we draw the line? Thorac Cardiovasc Surg. 2020 (e-pub ahead of print) DOI: 10.1055/s-0039-3402725
• 28 Vega J, Gordo M, Tascón A, Vélez S. Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. Emerg Radiol. 2020 (e-pub ahead of print) DOI: 10.1007/s10140-020-01806-0
• 29 Iba T, Levy J, Levi M, Connors J, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020 (e-pub ahead of print) DOI: 10.1097/CCM.0000000000004458